Kids' Weight-Loss Drug Prescriptions Jumped 310x Since 2019

A study out of NYU Langone Health contains a number that stops you cold: weight-loss drug prescriptions for children ages eight to eleven with obesity were 310-fold higher in June 2026 than when doctors first started writing them in 2019. The research, published September 4 in the journal Pediatrics, looked at the medical records of more than three and a half million children, and found that the share of eight-to-eleven-year-olds with obesity and no diabetes who had received a prescription climbed from 0.03 percent back then to 9.3 percent this year.

The medications at the center of it are the GLP-1s, appetite-dampening drugs originally developed for Type 2 diabetes in adults. Names like Wegovy, Zepbound and Saxenda are familiar from adult use, and the Food and Drug Administration has approved some of them for weight loss in patients as young as twelve. Below that cutoff, any prescription for a child is off-label, meaning it is not FDA-approved but remains legal when a doctor judges it appropriate. Washington Square News reported that clinical guidelines already allow these medications for children as young as eight.

What the numbers actually show

The headline figure is dramatic, but the researchers behind it keep urging people to read past it. In absolute terms, the study identified twenty thousand two hundred eighty-two children between eight and eleven who were prescribed the drugs over the full seven-and-a-half-year window, a tiny fraction of the roughly three point three million children in that age group estimated to have obesity in the United States. Orandi told Washington Square News in an interview: "The number of kids that need this treatment is still a very small minority." What matters, he said, is who those kids are. "The ones who are getting treated tend to have the most severe obesity, and/or they have complications of obesity, like obstructive sleep, pre-diabetes and steatotic liver disease."

That picture is borne out in the data. According to News-Medical, which covered the study findings in detail, 93.7 percent of the young children prescribed the drugs had severe obesity, meaning their body mass index ranked far above nearly all other children of the same age and sex. Roughly two in three of them, 65.2 percent, were already dealing with at least one obesity-linked condition such as high cholesterol, high blood pressure or sleep apnea. Older children with obesity were prescribed the drugs more often than younger ones, at 0.9 percent compared with 0.6 percent, and girls received prescriptions more often than boys. None of this surprised the research team, who framed the paper as the first national overview of how these drugs are being used in young children rather than an alarm bell.

The price tag, and who can pay it

One of the study's more uncomfortable findings has nothing to do with medicine. Children with obesity living in upper-income neighborhoods were 55 percent more likely to be prescribed the drugs than their lower-income peers, evidence of a growing divide in who can actually get them. As the study authors noted, weight-loss drug prescriptions are concentrating where families can afford them, not necessarily where the need is greatest. General pediatrician Mary Jo Messito, one of the study's authors, told Washington Square News that the cheapest patients could expect to pay out of pocket was roughly three hundred dollars a month, which she called a huge barrier. She said the research team wants to advocate with insurance companies and state and local governments to get coverage expanded.

There is also the question nobody can answer yet: what happens to a child who starts one of these medications and stays on it for years. The researchers are direct about that gap. Clinical trials of the drugs in children as young as six are already underway, and the team says long-term monitoring of the children already receiving prescriptions is still needed to confirm the medications stay safe and effective. "The most important question is: What happens to kids when you give them these medications?" senior author Allan Massie told Washington Square News. "The next step is to try to understand the outcome and ultimately, hopefully, inform pediatricians who want guidance about what might happen to a kid who starts" one of the drugs.

It helps to keep the scale in view. About one in five children in the United States has obesity, defined as a body mass index above the ninety-fifth percentile for their age and sex, yet child obesity remains understudied, something Massie noted in the same interview. The drugs reached only a small slice of the children who might qualify, which is exactly the point Orandi keeps returning to. As he put it, the real concern is not that more children are being treated. It is that so many children already have obesity and its complications that treatment is on the table at all. For parents watching this story, the takeaway is less about any single prescription than about a health problem big enough that doctors are reaching for tools they would not have considered a few years ago.

The basics still matter, and recent GenZNewZ reporting keeps finding the same throughline: long walks beat short bursts for heart health, gut bacteria may be running your rest, and teen mental health numbers are finally turning a corner.